Biomarin Pharmaceutical Stock

$57.41

0.16%

Nasdaq, Jul 07, 10:09 pm CET

ISIN

US09061G1013

Symbol

BMRN

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Biomarin Pharmaceutical Stock price

$57.41

-70.57 55.14% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.09 0.16%

ISIN

US09061G1013

Symbol

BMRN

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$11.0b

Enterprise Value

$10.3b

Net debt

positive

Cash

$1.3b

Shares outstanding

191.8m

Valuation (TTM | estimate)

P/E

21.6 | 16.3

P/S

3.7 | 3.4

EV/Sales

3.5 | 3.2

EV/FCF

16.7

P/B

1.9

Financial Health

Equity Ratio

81.0%

Return on Equity

7.5%

ROCE

10.9%

ROIC

10.0%

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

$3.0b | $3.2b

EBITDA

$745.8m | $916.7m

EBIT

$712.0m | $839.4m

Net Income

$523.9m | $675.9m

Free Cash Flow

$620.2m

Growth (TTM | estimate)

Revenue

19.4% | 12.2%

EBITDA

235.3% | 49.5%

EBIT

301.6% | 47.3%

Net Income

155.0% | 58.3%

Free Cash Flow

280.0%

EPS

$2.7

FCF per Share

$3.2

Short interest

3.0%

Employees

Rev per Employee

$940.0k

As a Free StocksGuide user, you can view scores for all 6,969 stocks worldwide.

Get Started for Free Today

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

??

35 Analysts have issued a Biomarin Pharmaceutical forecast:

28x Buy

80%

7x Hold

20%

More details on Analyst Estimates Including Price Targets

35 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2,950 2,950	19% 19% 100%
- Direct Costs	607 607	18% 18% 21%
Gross Profit	2,344 2,344	20% 20% 79%
- Selling and Administrative Expenses	897 897	5% 5% 30%
- Research and Development Expense	701 701	10% 10% 24%
EBITDA	746 746	235% 235% 25%
- Depreciation and Amortization	34 34	25% 25% 1%
EBIT (Operating Income) EBIT	712 712	302% 302% 24%
Net Profit	524 524	155% 155% 18%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Biomarin Pharmaceutical Stock News

Neutral

PRNewsWire

●

7 days ago

BioMarin Announces Completion of Acquisition of Inozyme

SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million.

Neutral

PRNewsWire

●

14 days ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif. , June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN ® (valoct...

Positive

The Motley Fool

●

about one month ago

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.

More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office	United States
CEO	Alexander Hardy
Employees	3,040
Founded	1997
Website	www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now